This protocol addresses malignant phyllodes tumour of the breast that has progressed to distant metastasis. Malignant phyllodes tumours carry an approximately 20% risk of distant spread, most commonly to the lungs, typically arising within two years of primary treatment.
Metastatic malignant phyllodes tumour is managed in line with guidelines for soft tissue sarcomas. Lung metastases are the most frequent site of distant spread, and recognition of this pattern is important for surveillance and timely intervention.
Malignant PT also carry a risk of distant metastasis of approximately 20%, mostly to the lungs, which tends to occur within 2 years of primary treatment.
Metastatic malignant PT should be managed as per local guidelines for STS (evidence/grade V/A).
In the second-line setting, partial responses were observed with cisplatin, doxorubicin, and regorafenib, and the response rates with first- and second-line chemotherapy were 31.4% and 16.7% respectively.
View source ↗